These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38766099)

  • 1. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
    bioRxiv; 2024 May; ():. PubMed ID: 38766099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Knudsen LA; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
    Oncogene; 2024 Oct; 43(43):3197-3213. PubMed ID: 39266679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
    Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
    Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
    Luo J; Chen Z; Qiao Y; Tien JC; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
    bioRxiv; 2024 May; ():. PubMed ID: 38586029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-4 activates androgen receptor through CBP/p300.
    Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
    Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
    Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
    Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
    Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
    Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
    Waddell AR; Huang H; Liao D
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer.
    Pimenta R; Camargo JA; Candido P; Ghazarian V; Gonçalves GL; Guimarães VR; Romão P; Chiovatto C; Mioshi CM; Dos Santos GA; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Viana NI; Reis ST
    Cell Physiol Biochem; 2022 Dec; 56(S4):1-15. PubMed ID: 36458578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
    Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
    Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    Ma M; Li M; Zhang C; Yang Z; Chen X; Lu P; Nie S; Zhang S; Ma S; Qin C
    J Med Chem; 2024 Sep; ():. PubMed ID: 39344125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
    Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
    Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
    Jin L; Garcia J; Chan E; de la Cruz C; Segal E; Merchant M; Kharbanda S; Raisner R; Haverty PM; Modrusan Z; Ly J; Choo E; Kaufman S; Beresini MH; Romero FA; Magnuson S; Gascoigne KE
    Cancer Res; 2017 Oct; 77(20):5564-5575. PubMed ID: 28819026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and function of androgen receptor coactivators in prostate cancer.
    Culig Z; Comuzzi B; Steiner H; Bartsch G; Hobisch A
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):265-71. PubMed ID: 15663989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
    Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
    J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells.
    Filon M; Yang B; Purohit TA; Schehr J; Singh A; Bigarella M; Lewis P; Denu J; Lang J; Jarrard DF
    Oncotarget; 2023 Jul; 14():738-746. PubMed ID: 37477521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
    Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
    J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.
    Culig Z
    J Cell Physiol; 2016 Feb; 231(2):270-4. PubMed ID: 26201947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.
    Heemers HV; Schmidt LJ; Kidd E; Raclaw KA; Regan KM; Tindall DJ
    Prostate; 2010 Jun; 70(9):959-70. PubMed ID: 20166126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer.
    Xu S; Fan L; Jeon HY; Zhang F; Cui X; Mickle MB; Peng G; Hussain A; Fazli L; Gleave ME; Dong X; Qi J
    Cancer Res; 2020 Aug; 80(15):3074-3087. PubMed ID: 32522824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.